• A case of glycogen storage disease type a with gout as the first manifestation
• A case of glycogen storage disease type Ⅰa with gout as the first manifestation
• A case report of glycogen storage disease type 1a
• A case study of a liver transplant-treated patient with glycogen storage disease type Ia presenting with multiple inflammatory hepatic adenomas: an analysis of clinicopathologic and genetic data
• A glycogen storage disease type 1a patient with type 2 diabetes
• A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets
• A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>T
• A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>T
• Aberrant glucose metabolism underlies impaired macrophage differentiation in glycogen storage disease type Ib
• Amnio acid substitution at position 298 of human glucose-6 phosphatase-α significantly impacts its stability in mammalian cells
• Assessment of auditory functions in patients with hepatic glycogen storage diseases
• Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation
• Biochemistry, Glycogenesis
• Biochemistry, Glycogenesis
• Blood glucose trends in glycogen storage disease type Ia: A cross-sectional study
• Body composition in patients with hepatic glycogen storage diseases
• Case report: The success of empagliflozin therapy for glycogen storage disease type 1b
• Clinical characteristics and genetic analysis of a Chinese pedigree affected by glycogen storage disease type Ia with gout as the first manifestation
• Clinical characteristics and long-term outcomes of patients with glycogen storage disease type 1b: a retrospective multi-center experience in Poland
• Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study
• CRISPR/Cas9-based double-strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type-Ia
• CT findings of glycogen storage disease I complicated with pancreatitis: A case report
• Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
• Cytokine profiling in patients with hepatic glycogen storage disease: Are there clues for unsolved aspects?
• Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b
• DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia
• Dental rehabilitation in a young patient with glycogen storage disease type 1B
• Development of hepatocellular adenomas in a patient with glycogen storage disease Ia treated with growth hormone therapy
• Development of minimally invasive (13)C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia
• Development of minimally invasive ¹³C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia
• Diabetes in a Patient with Glycogen Storage Disease Type 1a
• Dynamic Methods for Childhood Hypoglycemia Phenotyping: A Narrative Review
• Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire
• Elucidation of intermolecular interactions between chlorogenic acid and glucose-6-phosphate translocase: A step towards chemically induced glycogen storage disease type 1b model
• Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b
• Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial
• Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose
• Euglycemic Diabetic Ketoacidosis Presenting as Hypoglycemia in a Patient With Type 2 Diabetes and Von Gierke's Disease
• First report of suspected glycogen storage disease type 1a occurring in an adult dog
• Fluorodeoxyglucose-positron emission tomography as a potential alternative tool for functional diagnosis of glycogen storage disease type I
• Gene therapy and genome editing for type I glycogen storage diseases
• Gene therapy for glycogen storage diseases
• Genetics of severe congenital neutropenia as a gateway to personalized therapy
• Genome editing using <em>Staphylococcus aureus</em> Cas9 in a canine model of glycogen storage disease Ia
• Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia
• Genotypic and phenotypic features of 39 Chinese patients with glycogen storage diseases type I, VI, and IX
• Glycogen Storage Disease Type I
• Glycogen Storage Disease Type I
• Glycogen Storage Disease Type I With Hypercalcemia in an Infant: A Case Report
• Glycogen storage disease type I: Genetic etiology, clinical manifestations, and conventional and gene therapies
• Glycogen Storage Disease type IA refractory to cornstarch: Can next generation sequencing offer a solution?
• Glycogen Storage Disease Type IXb in a 3-y-old Child
• Glycogen storage disease type V: a still under-recognized condition lacking definitive genotype-phenotype correlates
• Glycogen Storage Disease: Expert Opinion on Clinical Diagnosis Revisited after Molecular Testing
• Glycogen storage diseases
• Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI
• Gut Dysbiosis Drives Inflammatory Bowel Disease Through the CCL4L2-VSIR Axis in Glycogen Storage Disease
• Hepatic ChREBP orchestrates intrahepatic carbohydrate metabolism to limit hepatic glucose 6-phosphate and glycogen accumulation in a mouse model for acute Glycogen Storage Disease type Ib
• Impact of hematopoietic stem cell transplantation in glycogen storage disease type Ib: A single-subject research design using (13)C-glucose breath test
• Impact of hematopoietic stem cell transplantation in glycogen storage disease type Ib: A single-subject research design using ¹³C-glucose breath test
• Inhibition of Wnt/beta-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia
• Inhibition of Wnt/β-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia
• Intestinal microbiota composition of children with glycogen storage Type I patients
• Intestinal stricture in a patient with glycogen storage disease type Ib and inflammatory bowel disease
• Investigation on the treatment of empagliflozin in glycogen storage disease type b
• Isolated short stature as the only presenting symptom of glycogen storage disease type 0a in a Chinese child: A case report
• Liver transplantation in glycogen storage disease: a single-center experience
• Long-Term Treatment of Lipoprotein Lipase Deficiency with Medium-Chain Triglyceride-Enriched Diet: A Case Series
• Molecular and clinical profiling in a large cohort of Asian Indians with glycogen storage disorders
• Molecular mechanism underlying impaired hepatic autophagy in glycogen storage disease type Ib
• Molecular mechanisms of aberrant neutrophil differentiation in glycogen storage disease type Ib
• Molecular, Biochemical, and Clinical Characterization of Thirteen Patients with Glycogen Storage Disease 1a in Malaysia
• Mutational analysis and clinical investigations of medically diagnosed GSD 1a patients from Pakistan
• Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin
• Novel mutation of SLC37A4 in a glycogen storage disease type Ib patient with neutropenia, horseshoe kidney, and arteriovenous malformation: a case report
• Parenteral Exposure of Mice to Ricin Toxin Induces Fatal Hypoglycemia by Cytokine-Mediated Suppression of Hepatic Glucose-6-Phosphatase Expression
• Pathogenic Potential of a PCK1 Gene Variant in Cytosolic PEPCK Deficiency: A Compelling Case Study
• Peripheral neuropathy caused by vitamin B(12) deficiency in a patient with glycogen storage disease type a
• Peripheral neuropathy caused by vitamin B₁₂ deficiency in a patient with glycogen storage disease type Ⅰa
• Persistent acidosis and chronic kidney disease in a patient with type 1 glycogen storage disease
• Potential use of other starch sources in the treatment of glycogen storage disease type Ia - an in vitro study
• Previously undiagnosed genetic disease in adult patient with hepatic masses and reported history of congenital hyperinsulinism
• Recurrent pancreatitis and sepsis in glycogen storage disease type Ia caused by complex heterozygous mutations in 2 sisters: Case report
• Report of an Iranian child with chronic abdominal pain and constipation diagnosed as glycogen storage disease type IX: a case report
• Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value-based healthcare approach and systematic benefit-risk assessment
• Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia
• Serum sex hormone-binding globulin levels are reduced and inversely associated with intrahepatic lipid content and saturated fatty acid fraction in adult patients with glycogen storage disease type 1a
• Short-term efficacy of empagliflozin in children with glycogen storage disease type b
• Short-term efficacy of empagliflozin in children with glycogen storage disease type Ⅰb
• SLGT2 Inhibitor Rescues Myelopoiesis in G6PC3 Deficiency
• Studies on glycogen storage disease type 1a animal models: a brief perspective
• Successful Anesthetic Management of an Adult Patient With Glycogen Storage Disease Type 1 During Liver Transplant: A Case Report
• Successful Treatment of Refractory Anemia in a Patient With Glycogen Storage Disease Type Ia Undergoing Hemodialysis
• Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5
• Systematic literature review of the epidemiology of glycogen storage disease type 1a
• Three novel SLC37A4 variants in glycogen storage disease type 1b and a literature review
• Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop
• Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre
• Urine-Derived Epithelial Cells as a New Model to Study Renal Metabolic Phenotypes of Patients with Glycogen Storage Disease 1a
• Von Gierke Disease (Glycogen Storage Disease Type I) and Life-Threatening Abdominal Aortic Aneurysm: A Case Report of an Extremely Rare Condition